食品与发酵工业 >

2026 , Vol. 52 >Issue 11: 65 - 73

DOI: https://doi.org/10.13995/j.cnki.11-1802/ts.044978

研究报告

基于宏基因组分析的动物双歧杆菌乳亚种BL-99发酵酸奶对人体肠道菌群的调节作用

  • 王红艳 ,
  • 韩敏 ,
  • 刘蕊 ,
  • 程坤 ,
  • 穆帅成 ,
  • 宋智泉 ,
  • 刘艺茹 ,
  • 徐进
展开
  • 1(中国疾病预防控制中心营养与健康所, 北京, 100050)
    2(国家食品安全风险评估中心, 北京, 100022)
    3(中国食品发酵工业研究院有限公司, 中国工业微生物菌种保藏管理中心, 北京, 100015)
第一作者:硕士研究生(刘艺茹工程师和徐进研究员为共同通信作者,E-mail:rita@china-cicc.org;xujin@cfsa.net.cn)

收稿日期: 2025-10-29

  修回日期: 2026-01-26

  网络出版日期: 2026-06-24

基金资助

国家食品安全风险评估中心青年科研基金项目(2025004)

收起

Effect of yoghurt fermented by Bifidobacterium animalis subsp.lactis BL-99 on gut microbiota based on metagenomic analysis

  • WANG Hongyan ,
  • HAN Min ,
  • LIU Rui ,
  • CHENG Kun ,
  • MU Shuaicheng ,
  • SONG Zhiquan ,
  • LIU Yiru ,
  • XU Jin
Expand
  • 1(National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Beijing 100050, China)
    2(China National Center for Food Safety Risk Assessment, Beijing 100022, China)
    3(China National Research Institute of Food & Fermentation Industries, China Center of Industrial Culture Collection, Beijing 100015, China)

Received date: 2025-10-29

  Revised date: 2026-01-26

  Online published: 2026-06-24

Fold

摘要

目前便秘已成为影响生活质量的重要因素,某些益生菌可能通过调节肠道菌群缓解便秘症状。然而,益生菌的功能具有高度菌株特异性,因此其作用需在菌株水平上进行评估。这项以干预前后自身为对照的临床试验旨在探讨动物双歧杆菌乳亚种BL-99干预便秘人群肠道菌群变化及功能通路差异。该研究纳入21名存在便秘困扰的受试者进行试验,服用含BL-99的发酵酸奶(1×1011 CFU/d),设置干预期4周,跟踪期2周。收集便秘患者症状自评量表和粪便,以干预前后自身为对照,将粪便进行宏基因组测序后重建基因组进行分析。结果表明,BL-99干预后,受试者的便秘症状得到有效改善,且效果持续至干预结束后至少2周。动物双歧杆菌_B和未分类的双歧杆菌平均相对丰度显著升高(P<0.05),干预前后的差异基因富集于氨基酸生物合成、辅酶因子生物合成、核糖体等KEGG通路中,碳水化合物活性酶分析显示,差异基因主要集中在糖苷水解酶家族13、糖基转移酶家族2和碳水化合物结合模块48。综上所述,动物双歧杆菌_B和未分类的双歧杆菌可作为BL-99改善便秘症状的生物标志物,BL-99干预可引起氨基酸生物合成通路、相关的碳水化合物活性酶等功能的改变,为其改善便秘提供了理论依据。

关键词： 动物双歧杆菌乳亚种BL-99; 宏基因组测序; 肠道菌群

本文引用格式

王红艳 , 韩敏 , 刘蕊 , 程坤 , 穆帅成 , 宋智泉 , 刘艺茹 , 徐进 . 基于宏基因组分析的动物双歧杆菌乳亚种BL-99发酵酸奶对人体肠道菌群的调节作用[J]. 食品与发酵工业, 2026 , 52(11) : 65 -73 . DOI: 10.13995/j.cnki.11-1802/ts.044978

Abstract

Constipation has become an important factor affecting quality of life, and probiotics may improve constipation symptoms by modulating the gut microbiota.However, probiotic functions exhibit high strain specificity, necessitating evaluation at the strain level.This self-controlled clinical trial aimed to investigate changes in gut microbiota and functional pathways in constipated individuals following intervention with Bifidobacterium animalis subsp.lactis BL-99.This study enrolled 21 subjects suffering from constipation to undergo the trial, administering fermented yogurt containing BL-99 (1×1011 CFU/d) for a 4-week intervention period followed by a 2-week follow-up.This study collected patient assessment of constipation-symptom and fecal samples.Fecal samples underwent metagenomic sequencing and genome reconstruction for analysis using a self-controlled design.The results indicates that BL-99 intervention effectively improves constipation symptoms in participants, with effects persisting for at least two weeks post-intervention.The average relative abundance of Bifidobacterium animalis_B and unclassified Bifidobacterium significantly increase (P<0.05).Differential genes before and after intervention are enriched in KEGG pathways including biosynthesis of amino acids, biosynthesis of cofactors, and ribosome.Analysis of carbohydrate-active enzymes reveals that differential genes are primarily concentrated in glycoside hydrolase family 13, glycosyl transferase family 2, and carbohydrate-binding module family 48.These findings suggest that Bifidobacterium animalis_B and unclassified Bifidobacterium may serve as microbial markers for constipation relief efficacy by BL-99 intervention.BL-99 intervention induces functional alterations in biosynthesis of amino acids pathways and related carbohydrate-active enzymes, providing theoretical support for intervening in constipation.

Key words： Bifidobacterium animalis subsp.lactis BL-99; metagenomic sequencing; gut microbiota

参考文献

[1] CHEN S Y, LIN J L, HUANG M X, et al.The postbiotic of hawthorn-probiotic ameliorates constipation by multi-pathway inhibition of PANoptosis in intestinal epithelial cells[J].Frontiers in Immunology, 2025, 16:1622619.
[2] PARK C J, JONES M P, PROTT G, et al.Rome IV functional defecation disorder:Time for a change in symptom criteria for improved clinical relevance?[J].American Journal of Gastroenterology, 2025, 120(9):2165-2172.
[3] YURTDAŞ G, ACAR-TEK N, AKBULUT G, et al.Risk factors for constipation in adults:A cross-sectional study[J].Journal of the American College of Nutrition, 2020, 39(8):713-719.
[4] NARITA M, TSUTSUI M, MOCHIZUKI N, et al.Constipation in patients undergoing cardiac surgery:Incidence and risk factors[J].JTCVS Open, 2025, 28:387-396.
[5] MA J X, MA H L, ZHENG S B, et al.Intestinal flora in the constipation patients before versus after lactulose intervention[J].Medicine, 2023, 102(32):e34703.
[6] CAMILLERI M.Gastrointestinal motility disorders in neurologic disease[J].Journal of Clinical Investigation, 2021, 131(4):e143771.
[7] XU J L, WANG L, CHEN X, et al.New understanding on the pathophysiology and treatment of constipation in Parkinson’s disease[J].Frontiers in Aging Neuroscience, 2022, 14:917499.
[8] ANAND N, GORANTLA V R, CHIDAMBARAM S B.The role of gut dysbiosis in the pathophysiology of neuropsychiatric disorders[J].Cells, 2023, 12(1):54.
[9] VICENTINI F A, KEENAN C M, WALLACE L E, et al.Intestinal microbiota shapes gut physiology and regulates enteric neurons and Glia[J].Microbiome, 2021, 9:210.
[10] YANG L, WANG Y, ZHANG Y, et al.Gut microbiota:A new avenue to reveal pathological mechanisms of constipation[J].Applied Microbiology and Biotechnology, 2022, 106(21):6899-6913.
[11] JIN Y J, PARK Y J, CHOI J, et al.Impact of probiotic formula (lacto-5X) on constipation:Improvements in gastrointestinal symptoms, gut microbiome, and metabolites[J].Journal of Microbiology and Biotechnology, 2025, 35:e2412056.
[12] TAKEDA T, ASAOKA D, NOJIRI S, et al.Usefulness of Bifidobacterium longum BB536 in elderly individuals with chronic constipation:A randomized controlled trial[J].American Journal of Gastroenterology, 2023, 118(3):561-568.
[13] IBARRA A, LATREILLE-BARBIER M, DONAZZOLO Y, et al.Effects of 28-day Bifidobacterium animalis subsp.lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation:A double-blind, randomized, placebo-controlled, and dose-ranging trial[J].Gut Microbes, 2018, 9(3):236-251.
[14] CHENG J, GAO C, ALA-JAAKKOLA R, et al.Eight-week supplementation with Bifidobacterium lactis HN019 and functional constipation:A randomized clinical trial[J].JAMA Network Open, 2024, 7(10):e2436888.
[15] CHEN M, LIU C, DAI M Z, et al.Bifidobacterium lactis BL-99 modulates intestinal inflammation and functions in zebrafish models[J].PLoS One, 2022, 17(2):e0262942.
[16] LI M N, ZHANG Q, ZHAO W, et al.Effects and persistence of Bifidobacterium animalis subsp.lactis BL-99 and fructooligosaccharides on older adults with functional constipation:A randomized, double-blind, placebo-controlled trial[J].The Journal of Nutrition, Health and Aging, 2025, 29(8):100598.
[17] ZHANG Q, ZHAO W, LUO J, et al.Synergistic defecation effects of Bifidobacterium animalis subsp.lactis BL-99 and fructooligosaccharide by modulating gut microbiota[J].Frontiers in Immunology, 2025, 15:1520296.
[18] ZHANG Q, ZHAO W, ZHAO Y Y, et al.In vitro study of Bifidobacterium lactis BL-99 with fructooligosaccharide synbiotics effected on the intestinal microbiota[J].Frontiers in Nutrition, 2022, 9:890316.
[19] FAN Q X, GAO Y Y, ZHOU Y Q, et al.Weizmannia coagulans BC99 relieves constipation symptoms by regulating inflammatory, neurotransmitter, and lipid metabolic pathways:A randomized, double-blind, placebo-controlled trial[J].Foods, 2025, 14(4):654.
[20] LI D H, LIU C M, LUO R B, et al.MEGAHIT:An ultra-fast single-node solution for large and complex metagenomics assembly via succinct de Bruijn graph[J].Bioinformatics, 2015, 31(10):1674-1676.
[21] KANG D D, LI F, KIRTON E, et al.MetaBAT 2:An adaptive binning algorithm for robust and efficient genome reconstruction from metagenome assemblies[J].PeerJ, 2019, 7:e7359.
[22] CHKLOVSKI A, PARKS D H, WOODCROFT B J, et al.CheckM2:A rapid, scalable and accurate tool for assessing microbial genome quality using machine learning[J].Nature Methods, 2023, 20(8):1203-1212.
[23] OLM M R, BROWN C T, BROOKS B, et al.dRep:A tool for fast and accurate genomic comparisons that enables improved genome recovery from metagenomes through de-replication[J].The ISME Journal, 2017, 11(12):2864-2868.
[24] CHAUMEIL P A, MUSSIG A J, HUGENHOLTZ P, et al.GTDB-Tk:A toolkit to classify genomes with the Genome Taxonomy Database[J].Bioinformatics, 2020, 36(6):1925-1927.
[25] HYATT D, CHEN G L, LOCASCIO P F, et al.Prodigal:Prokaryotic gene recognition and translation initiation site identification[J].BMC Bioinformatics, 2010, 11:119.
[26] CANTALAPIEDRA C P, HERNÁNDEZ-PLAZA A, LETUNIC I, et al.eggNOG-mapper v2:Functional annotation, orthology assignments, and domain prediction at the metagenomic scale[J].Molecular Biology and Evolution, 2021, 38(12):5825-5829.
[27] BUCHFINK B, XIE C, HUSON D H.Fast and sensitive protein alignment using DIAMOND[J].Nature Methods, 2015, 12(1):59-60.
[28] 胡薇薇, 马翠翠, 全柯谕, 等.肥胖儿童肠道菌群结构和功能的变化[J].中国食品学报, 2025, 25(8):21-32.
HU W W, MA C C, QUAN K Y, et al.Changes in the structure and function of the gut microbiota in obese children[J].Journal of Chinese Institute of Food Science and Technology, 2025, 25(8):21-32.
[29] NAN X M, ZHAO W, LIU W H, et al.Bifidobacterium animalis subsp.lactis BL-99 ameliorates colitis-related lung injury in mice by modulating short-chain fatty acid production and inflammatory monocytes/macrophages[J].Food & Function, 2023, 14(2):1099-1112.
[30] ZHANG Q, LI G, ZHAO W, et al.Efficacy of Bifidobacterium animalis subsp.lactis BL-99 in the treatment of functional dyspepsia:A randomized placebo-controlled clinical trial[J].Nature Communications, 2024, 15:227.
[31] LAI H, LI Y F, HE Y F, et al.Effects of dietary fibers or probiotics on functional constipation symptoms and roles of gut microbiota:A double-blinded randomized placebo trial[J].Gut Microbes, 2023, 15:2197837.
[32] GAO X Y, GUO K F, LIU S F, et al.A potential use of vidarabine:Alleviation of functional constipation through modulation of the adenosine A2A receptor-MLC signaling pathway and the gut microbiota[J].International Journal of Molecular Sciences, 2024, 25(23):12810.
[33] HE M L, WANG S Q, ZHANG J Y, et al.Analyzing the causal relationship between gut microbiota, metabolites, and constipation:A Mendelian randomization study[J].Medicine, 2025, 104(38):e44542.
[34] HUANG R H, ZHANG B B, WANG J, et al.Effect of dietary sugarcane bagasse on reproductive performance, constipation, and gut microbiota of gestational sows[J].Animals, 2024, 14(17):2523.
[35] SANTOS-MARCOS J A, MORA-ORTIZ M, TENA-SEMPERE M, et al.Interaction between gut microbiota and sex hormones and their relation to sexual dimorphism in metabolic diseases[J].Biology of Sex Differences, 2023, 14:4.
[36] GHOSH T S, SHANAHAN F, O’TOOLE P W.The gut microbiome as a modulator of healthy ageing[J].Nature Reviews.Gastroenterology & Hepatology, 2022, 19(9):565-584.
[37] GONZÁLEZ-MORELO K J, GALÁN-VÁSQUEZ E, MELIS F, et al.Structure of co-expression networks of Bifidobacterium species in response to human milk oligosaccharides[J].Frontiers in Molecular Biosciences, 2023, 10:1040721.
[38] MA W W, ZHAO Y Y, LIU Y Y, et al.Bifidobacterium animalis subsp.lactis TG11 ameliorates loperamide-induced constipation in mice by modulating gut microbiota[J].Frontiers in Microbiology, 2025, 16:1525887.
[39] O’CALLAGHAN A, VAN SINDEREN D.Bifidobacteria and their role as members of the human gut microbiota[J].Frontiers in Microbiology, 2016, 7:925.
[40] MILANI C, TURRONI F, DURANTI S, et al.Genomics of the genus Bifidobacterium reveals species-specific adaptation to the glycan-rich gut environment[J].Applied and Environmental Microbiology, 2016, 82(4):980-991.
[41] WEI Y, HUANG N, YE X Y, et al.The postbiotic of hawthorn-probiotic ameliorating constipation caused by loperamide in elderly mice by regulating intestinal microecology[J].Frontiers in Nutrition, 2023, 10:1103463.
[42] ZHANG Z, FANG Y J, HE Y L, et al.Bifidobacterium animalis Probio-M8 improves sarcopenia physical performance by mitigating creatine restrictions imposed by microbial metabolites[J].npj Biofilms and Microbiomes, 2024, 10:144.
[43] JI Z Y, XU M Z, JIN C.Correlation of gut dominant microbiota with hyperuricemia[J].Journal of Zhejiang University (Medical Sciences), 2023, 52(2):207-213.
Options
文章导航

/

〈 〉

技术支持：北京玛格泰克科技发展有限公司